We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > ublituximab

News List

Samsung Biologics, TG Therapeutics Expand Manufacturing Collaboration contractpharma
April 28, 2021
Samsung Biologics, a contract development and manufacturing organization (CDMO) and TG Therapeutics, are expanding a large-scale contract manufacturing deal for the supply of TG Therapeutics’ ublituximab, an investigational anti-CD20 monoclonal antibody.
TG Therapeutics’ ublituximab tops Sanofi’s Aubagio in MS trial pharmatimes
April 20, 2021
New York-headquartered biopharma company TG Therapeutics has revealed new data for its investigational therapy ublituximab, which demonstrated superiority over Sanofi’s Aubagio in patients with relapsing forms of multiple sclerosis (MS).